Catalyst Biosciences, Inc. (CBIO) |
|
0.3044 0.022 (7.94%)
|
02-02 16:00 |
|
Open: |
0.2951 |
Pre. Close: |
0.282 |
|
High:
|
0.3179 |
Low:
|
0.2951 |
|
Volume:
|
1,713,435 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 4:10:51 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.55 One year: 0.75 |
| Support: |
Support1: 0.2 Support2: 0.16 |
| Resistance: |
Resistance1: 0.47 Resistance2: 0.64 |
| Pivot: |
0.3  |
| Moving Average: |
MA(5): 0.29 MA(20): 0.38
MA(100): 0.5 MA(250): 0.39 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 20.2 %D(3): 19.8 |
| RSI: |
RSI(14): 34.9 |
| 52-week: |
High: 1.82 Low: 0.09 |
| Average Vol(K): |
3-Month: 862 (K) 10-Days: 840 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CBIO ] has closed below upper band by 49.5%. Bollinger Bands are 146.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.29 - 0.29 |
0.29 - 0.29 |
|
Low:
|
0.28 - 0.28 |
0.28 - 0.28 |
|
Close:
|
0.28 - 0.28 |
0.28 - 0.28 |
|
Company Description |
|
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California. |
Headline News |
Thu, 02 Feb 2023
Is Catalyst Biosciences Inc (CBIO) Stock a Smart Investment Thursday? - InvestorsObserver
Thu, 02 Feb 2023
SHAREHOLDER ALERT: Weiss Law Reminds SHBI, CBIO, AJRD, and SAL Shareholders About Its Ongoing Investigati - Benzinga
Thu, 26 Jan 2023
SHAREHOLDER ALERT: Weiss Law Reminds CBIO, AJRD, SAL ... - PR Newswire
Wed, 25 Jan 2023
Catalyst Biosciences Inc. (CBIO): Is this the Most Sought-After Stock ... - Invest Chronicle
Wed, 25 Jan 2023
Where Will Catalyst Biosciences Inc (CBIO) Stock Go Next After It ... - InvestorsObserver
Tue, 24 Jan 2023
There Is Still Room For Catalyst Biosciences Inc. (CBIO) to Improve ... - The Dwinnex
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
2.116e+007 (%) |
|
% Held by Institutions
|
26 (%) |
|
Shares Short
|
536 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.039e+007 |
|
EPS Est Next Qtl
|
-1.55 |
|
EPS Est This Year
|
-7.91 |
|
EPS Est Next Year
|
-4.81 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
367.4 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
259.3 |
|
Return on Equity (ttm)
|
-46.5 |
|
Qtrly Rev. Growth
|
3.23e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
19.1 |
|
EBITDA (p.s.)
|
-4.70362e+007 |
|
Qtrly Earnings Growth
|
0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-49 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0.01 |
|
Price to Cash Flow
|
0.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
429890 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-02-12 |
|
Ex-Dividend Date
|
2015-08-19 |
|
Your Ad Here
|
|
